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Background. Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit.
Methods. After initiation of zidovudine, lamivudine, abacavir, and amprenavir therapy in patients in the QUEST cohort, predictors of virological outcome, virological and immunological changes, and adverse events were evaluated over 48 weeks.
Results. One hundred forty-eight patients started antiretroviral therapy during primary HIV-1 infection with р3 bands on Western Blot (median plasma HIV-1 RNA load, 5.4 log copies/mL; median CD4 cell count, 517 cells/mm 3 ). By week 48, 36% of patients had stopped treatment or were lost to follow-up. Among the 115 patients receiving follow-up care at week 48 (102 of whom were receiving antiretroviral therapy), the median viral load decrease was Ϫ5.4 log copies/mL (interquartile range [IQR] , Ϫ6.4 to Ϫ3.9 log copies/mL), and the median increase in CD4 cell count was 147 cells/mm 3 (IQR, Ϫ1 to 283 cells/mm 3 ); 84.2% of patients had a viral load р50 copies/ mL, and 44.7% of patients had a viral load р3 copies/mL. The median cell-associated RNA level decreased from 3.4 log copies/million PBMCs (IQR, 2.9-4.1 log copies/million PBMCs) to 0.8 log copies/million PBMCs (IQR, 0.5-1.4 log copies/million PBMCs), and the median cell-associated DNA level decreased from 2.8 log copies/ million PBMCs (IQR, 2.4-3.0 log copies/million PBMCs) to 1.6 log copies/million PBMCs (IQR, 1.2-1.9 log copies/million PBMCs); 33.3% of patients had an undetectable RNA level, and 9.5% of patients had an undetectable cell-associated DNA level. The median CD8 + /CD38 ++ T cell count decreased from 459 cells/mm 3 (IQR, ) to 33 cells/mm 3 (IQR, . Baseline CD8 + /CD38 ++ T cell count and cell-associated DNA level were independent inverse predictors for reaching a viral load р3 copies/mL. Eighty-three patients experienced a serious adverse event (median duration of an adverse event, 15 days).
Conclusions. Initiation of antiretroviral therapy during primary HIV-1 infection was associated with very significant antiretroviral activity and a decrease in immune activation. Lower baseline CD8 + /CD38 ++ T cell count and cell-associated DNA level were predictive of achieving a viral load р3 copies/mL.
It is unclear whether initiation of potent antiretroviral therapy (ART) during primary HIV-1 infection (PHI) can alter long-term prognosis [1] [2] [3] [4] [5] . Early ART can gence of resistance in noncompliant patients. Therefore, it is of interest to evaluate the parameters associated with optimal responses to early treatment and toxicity, which may affect responses to treatment.
Herein, we report the baseline characteristics, treatment continuation rates, virological and immunological responses, and safety parameters over 48 weeks after ART initiation, together with the predictors of virological control, in the largest therapeutic cohort of patients who were prospectively enrolled during PHI.
METHODS

Study patients.
Patients aged у18 years were recruited from 39 health care facilities in 10 countries (including Canada and Australia and European countries) if they had a negative HIV ELISA result or р3 bands on Western Blot, in addition to one of the following characteristics: p24 antigenemia, a PCR result that was positive for HIV-1 RNA or DNA, or detectable viral activity by other RNA and DNA quantification methods.
Study design. The design, methods, and outcome measures of the study have been described previously [15] . Eligible patients initiated therapy with the following drugs, which were administered twice daily: 300 mg of zidovudine plus 150 mg of lamivudine, 300 mg of abacavir, and 1200 mg of amprenavir. Alteration to this initial regimen was allowed for treatmentlimiting toxicities or compliance issues.
Ethics. All patients provided signed informed consent prior to study enrollment. Independent local ethics committees reviewed and approved the study protocol and its amendments. An independent data safety and monitoring board monitored the progress of the trial.
Measurements and evaluations. At enrollment, physicians recorded the patient's medical history, risk factors for HIV acquisition, and symptoms and signs of PHI (with date of onset) and performed a clinical examination. Baseline blood sample examination included safety parameters and immunological and virological studies. After enrollment, clinical status and adverse events were recorded. Safety parameters, plasma HIV-1 RNA load, and CD4, CD8, and CD8 + /CD38 ++ T cell counts were obtained at regular intervals. Cell-associated DNA and RNA levels were determined for European and Australian patients at baseline and at weeks 4, 12, 24, 36, and 42. Laboratory methods. Routine complete blood cell counts, biochemistry values, HIV-1 loads, and CD4 and CD8 cell counts were measured at central laboratories. The Amplicor Monitor (Roche Molecular Diagnostics; lower limit of detection, 400 copies/mL) was used to quantify HIV-1 load. Samples with HIV-1 loads !400 copies/mL were reanalyzed with the Ultrasensitive Monitor assay, version 1.5 (limit of detection, 50 copies/mL). The Ultraboosted assay was used to determine viral loads !3 copies/mL at strategic time points, when the viral load was !50 copies/mL [7] . CD8 + /CD38 ++ T cell counts were quantitated at the HIV Immunology Unit at the Royal Free Hospital (London, United Kingdom) and at the Centre for Immunology at National Centre in HIV Epidemiology and Clinical Research (Sydney, Australia), as previously described [7] . A normal CD8 + /CD38 ++ T cell count was defined as a count !20 cells/ mm 3 [16] . Cell-associated HIV-1 DNA and RNA assays were performed at the Central Virology Laboratory at Geneva University Hospital (Geneva, Switzerland) (limit of detection, 3 copies/million PBMCs) [7] .
Genotypic analysis. Sequence analysis of HIV-1 gag region and protease coding region and RT-PCR were performed at baseline (VircoGEN HIV-1 report; Virco).
Statistical methods. Virological and immunological parameters during follow-up and changes from baseline were summarized by median and interquartile range (IQR) values, using data from all patients with measurements available, regardless of whether the patient was receiving ART. KaplanMeier analysis was used to assess changes from baseline in log 10 HIV-1 load and cell-associated DNA and RNA levels to account for the lower limit of detection of assays [17] . Additional analyses of the proportion of patients over time with HIV-1 loads р50 copies/mL, р10 copies/mL, or р3 copies/mL used (1) an intention-to-treat approach and (2) a "receiving ART" analysis. Associations between variables were assessed using Spearman's rank correlation coefficients. Continuous variables were compared between subgroups using the Mann-Whitney U test. Kaplan-Meier estimates were used to examine the probability of ART discontinuation and change according to various end points, including the time to achieve an HIV-1 load р3 copies/ mL and the occurrence of a serious or grade 3 or 4 adverse event. Cox proportional hazards regression (stratified by country) was used to investigate factors associated with these end points. Results are presented as hazard ratios (HRs) with 95% CIs.
RESULTS
Patient population and baseline characteristics.
From February 1998 through October 1999, 148 enrolled patients started ART. The demographic and baseline characteristics of the patients are shown in table 1. The majority of the patients were men who had sex with men and were symptomatic during PHI (90% of patients; fever was reported for 66% of these patients, malaise for 54%, lethargy for 53%, headache for 44%, myalgia for 42%, rash for 40%, gastrointestinal symptoms for 39%, and weight loss for 37%). Treatment was initiated within 1 and 2 weeks of diagnosis in 64% and 83% of patients, respectively.
Patient follow-up and treatment changes. Thirty-three patients (22.3%) withdrew from follow-up prior to week 48 (12 patients withdrew by choice, 8 withdrew because of adverse events, 6 were lost to follow-up, and 7 withdrew because of another or unknown reason). Thirty of the patients who withdrew from follow-up had stopped ART at the last recorded follow-up visit. Among 115 patients still receiving follow-up care at week 48, 13 (11.3%), 23 (20%), 78 (67.8%), and 1 (1%) were receiving 0, 3, 4, and 5 drugs (excluding ritonavir, given as protease inhibitor booster), respectively, with the following regimens: nucleoside reverse-transcriptase inhibitors and a protease inhibitor (administered to 93 patients), a nucleoside reverse-transcriptase inhibitor and nonnucleoside reverse-transcriptase inhibitors (administered to 2 patients), and nucleoside reverse-transcriptase inhibitors alone (administered to 7 patients). Fifty-eight patients continued to receive their initial ART regimen, and 86, 85, and 73 patients continued to receive abacavir, zidovudine plus lamivudine, and amprenavir, respectively. At week 48, 20 (17.4%) of 115 patients had discontinued ART for у7 days (8 patients discontinued ART because of noncompliance, 5 because of adverse events, 2 by choice, and 5 because of an other or unknown reason), and 62 (53.9%) of 115 patients had changed their initial regimen (defined as discontinuation of any drug for у7 days or addition of a new drug). Figure 1 shows Kaplan-Meier cumulative proportions over time for 3 outcomes, including study withdrawal (outcome A; 33 patients), study withdrawal or discontinuation of ART for у7 days (outcome B; 53 patients), and study withdrawal or regimen change (outcome C; 95 patients), with percentages at week 48 of 22.3%, 35.8%, and 64.2%, respectively. The rate of discontinuation or change of ART was high during the first 2 months and decreased over time ( , , and P p .22 P p .006 , by Poisson regression for linear trend in rate of out-P ! .001 comes A, B, and C, respectively, over four 12-week periods). In a Cox model of the association of baseline factors with outcome B, stratified by country of recruitment, older age, being a man who has sex with men, and higher baseline viral load were independently associated with a lower risk of study withdrawal and/or ART discontinuation (adjusted HR, 0. ], for being a man who has sex with men vs. other P p .046 sexual preferences); no association was found between study withdrawal and/or discontinuation of ART and baseline CD4 cell count or presence of symptoms of PHI ( , for adjusted P 1 .5 HRs).
Baseline plasma viral load and immunological parameters. The median HIV-1 load was 5.4 log copies/mL (range, 2.1-7.9 log copies/mL), and the median CD4 cell count was 514 cells/ mm 3 (range, 162-1380 cells/mm 3 ) (table 2) . Plasma viremia was inversely correlated with CD4 cell count (Spearman's correlation: ; ). Patients with symptoms tended r p -0.41 P ! .001 to have higher viral loads than did patients who did not have symptoms (5.5 log copies/mL vs. 4.9 log copies/mL; , P p .13 by Mann-Whitney U test). More recent symptom onset was associated with higher viral load and lower CD4 cell count. Correlations of time since symptom onset with viral load and CD4 cell count were Ϫ0.35 ( ) and 0.17 ( ), P ! .001 P p .052 respectively.
Baseline cell-associated RNA and DNA levels and correlation with viral load and CD4 cell counts. Cell-associated HIV-1 RNA and DNA levels were measured in 114 patients. The median HIV-1 RNA level was 3.4 log copies/million PBMCs (range, 0.9-5.9 log copies/million PBMCs), and the median cell-associated HIV-1 DNA level was 2.8 log copies/ million PBMCs (range, 1.2-4.0 log copies/million PBMCs) (table 2); these levels strongly correlated with HIV-1 load (Spearman's correlation: and , for RNA; r p 0.88 P ! .001 r p 0.64 and , for DNA). CD4 cell count was inversely correlated P ! .001 with cell-associated RNA level ( ; ) and cellr p Ϫ0.44 P ! .001 associated DNA level ( ; ). r p Ϫ0.31 P p .001 Baseline genotypic resistance. Genotyping performed for 132 patients revealed thymidine-associated mutations in 5 patients (4%), and 9 patients (7%) harbored other nucleoside reverse-transcriptase inhibitor-associated mutations (3 patients had mutations in codon 215, 3 had mutations in codon 184, and 3 had mutations in codon 41). One patient had a primary protease inhibitor-associated mutation, and none had nonnucleoside reverse-transcriptase inhibitor-associated mutations.
Changes in plasma viral load and immunological parameters after initiation of ART. HIV-1 load decreased over 48 weeks after ART initiation (table 2 and figure 2). Median changes adjusted for the limit of detection were Ϫ1.8 log copies/mL (IQR, Ϫ2.5 to Ϫ1.4 log copies/mL) at week 2, Ϫ3.4 log copies/mL (IQR, Ϫ4.2 to Ϫ2.7 log copies/mL) at week 12, and Ϫ5.4 log copies/mL (Ϫ6.4 to Ϫ3.9 log copies/ mL) at week 48. Corresponding changes unadjusted for the limit of detection at weeks 2, 12, and 48 were Ϫ1.8 log copies/ mL, Ϫ3.2 log copies/mL, and Ϫ4.7 log copies/mL, respectively. At week 48, 96 (84.2%) of 114 patients had a viral load р50 copies/mL, 71 (62.3%) of 114 patients had a viral load р10 copies/mL, and 51 (44.7%) of 114 patients had a viral load р3 copies/mL. CD4 cell count increased rapidly during the first 2 weeks of treatment, with little further increase at week 2. The median change in CD4 cell count at week 2 was +124 cells/mm 3 (table 2) . Changes in cell-associated HIV-1 RNA and DNA levels after initiation of ART. Changes of cell-associated HIV-1 RNA and DNA levels are shown in table 2 and figure 2. The cell-associated RNA level decreased rapidly during the first 4 weeks in parallel with HIV-1 load, with little further decrease thereafter. At week 42, the median RNA level was 0.8 log copies/million PBMCs (IQR, 0.48-1.43 log copies/million PBMCs) among 63 patients. The cell-associated DNA level decreased gradually over 42 weeks to reach a median level of 1.58 log copies/million PBMCs (IQR, 1.18-1.90 log copies/million PBMCs) among 63 patients. At week 42, levels !3 log copies/million PBMCs were noted in 21 (33.3%) of 63 patients and 6 (9.5%) of 58 patients for cellassociated RNA and DNA, respectively. Levels of cell-associated RNA and DNA at week 42 were associated with the viral load at week 48 ( , for cell-associated RNA level, and r p 0.42 r p , for cell-associated DNA level;
). Baseline cell-as-0.43 P ! .001 sociated DNA levels were also associated with cell-associated DNA levels at week 42 ( ; ). Two patients r p 0.43 P p .001 achieved undetectable levels according to all 3 measures (cellassociated RNA and DNA levels !3 log copies/million PBMCs and viral load р3 copies/mL) at week 42.
Baseline factors and time to achieve an HIV-1 load р3 copies/mL. Cumulative proportions of 78 patients with an HIV-1 load р3 copies/mL were 1.5%, 11.1%, 32.8%, 55.2%, and 63.4% by weeks 12, 20, 28, 36, and 48, respectively. In univariable Cox models stratified by country, baseline viral load, cell-associated RNA level, cell-associated DNA level, and CD8 + / CD38 ++ T cell count were each inversely associated with time to achieve a viral load р3 copies/mL (HRs for every 1 log higher value for each parameter were 0. ++ T cell count); CD4 cell count was not inversely associated with time to achieve a viral load р3 copies/mL (HR for every 100 cells higher, 1.04; 95% CI, . In a multivariable model, baseline CD8 + / CD38 ++ T cell count and cell-associated DNA level were independent predictors of a viral load р3 copies/mL among 103 patients (adjusted HR for every 1 log higher, 0.30 [95% CI, , for CD8 + /CD38 ++ T cell count). P p .016 Suppression of plasma viremia according to "intention-totreat" and "receiving ART" analyses. Figure 3 shows the proportion of patients with viral loads р50 copies/mL, р10 copies/ mL, and р3 copies/mL, by week of follow-up, using (1) an "intention-to-treat" analysis, in which all 148 patients were included at each time point, with missing data counted as "failure;" and (2) a "receiving ART" analysis, in which only patients receiving any type of ART were included at the time of viral load measurement. Using an intention-to-treat analysis, 64.9% (95% CI, 57.2%-72.6%), 48.0% (95% CI, 39.9%-56.0%), and 34.5% (95% CI, 26.8%-42.1%) of all 148 patients had viral loads р50 copies/mL, р10 copies/mL, and р3 copies/mL at week 48, respectively. Corresponding percentages for the receiving ART analysis were 94.0% (95% CI, 87.4%-97.8%), 69.05 (95% CI, 59.0%-77.9%), and 49.0% (95% CI, 38.9%-59.2%) among 100 patients. Overall, only 5 patients reached a viral load 1400 copies/mL during weeks 28-48 while receiving ART.
Safety and adverse events. Eighty-three clinical adverse events classified as grade 3 or 4 or serious adverse events occurred among 49 patients during the 48 weeks after ART initiation. The most common clinical adverse events were depression and/or attempted suicide (accounting for 11% of all serious adverse events or grade 3 or 4 clinical adverse events), rash (9%), vomiting (8%), nausea (7%), fever (6%), diarrhea (6%), and hypersensitivity to abacavir (6%). Of these 83 adverse events, 38 were considered to be related to study drug. One death due to gastrointestinal hemorrhage was considered to be unrelated to study drug. Ninety-three grade 3 or 4 laboratory abnormalities occurred among 45 patients (increased alanine aminotransferase [accounting for 19% of all grade 3 or 4 laboratory adverse events], amylase [19%] , aspartate aminotransferase [12%], and creatine phosphokinase levels [15%] and neutropenia [11%]). Cumulative percentages of patients having a serious or grade 3 or 4 adverse event during 4, 12, 24, and 48 weeks of ART initiation were 23.9%, 38.0%, 45.6%, and 58.5%, respectively. The median duration of an adverse event was 15 days, with 90% of adverse events occurring for !65 days. Thirty-two adverse events (in 22 patients) resulted in interruption (14 patients) or discontinuation (18 patients) of a drug. No patient developed AIDS during the study period.
DISCUSSION
Herein, we report the largest prospective therapeutic study of PHI. The majority of patients were men who have sex with Figure 2 . Median changes from baseline in plasma HIV-1 RNA load, cell-associated RNA and DNA levels, and CD4 cell count, by number of weeks after initiation of antiretroviral therapy (ART). Data include all patients who continued to receive follow-up care. Changes in plasma HIV-1 RNA load were adjusted for assay limit of detection.
men and were symptomatic during PHI. By week 48, 36% of the patients who had started receiving ART were either not receiving treatment or lost to follow-up, with an initial high rate of treatment change, which stabilized later during the study. The vast majority of patients who stopped receiving ART prematurely had undetectable HIV-1 loads when therapy was interrupted. ART initiation was associated with decreases in HIV-1 load and cell-associated RNA and DNA levels and an improvement in immunological parameters. Baseline CD8 + / CD38 ++ T cell count and cell-associated DNA level were independent predictors for achieving a viral load р3 copies/mL. Toxicity was generally reversible.
This study provides important information regarding the feasibility of starting quadruple ART in a large cohort of patients with PHI. Previous studies, which generally used 3 drugs, have shown treatment discontinuation rates of 19%-50% at 1 year [18] [19] [20] [21] . A recent diagnosis of HIV infection, a rapid lifechanging decision, clinical symptoms, and future rather than immediate administration of ART may compound the problems of treatment-related toxicity and high pill burden when comparing treatment discontinuation rates between patients with acute infection and those with chronic infection [22] . Kost et al. [22] revealed a higher number of patients stopping a similar ART regimen when they were treated during early infection, compared with those treated during chronic infection. Among newly infected patients, nonadherence and intolerance to adverse effects of therapy were the main reported reasons for stopping treatment. The availability of newer drugs with lower toxicities and pill counts may positively impact patients' adherence in future studies.
Our results confirm those from previous smaller studies of PHI that reveal the possibility of achieving an undetectable HIV-1 load [18] [19] [20] [21] [22] [23] [24] . The extent of virological control after ART initiation was further exemplified by the percentages of patients receiving ART at week 48 who had HIV-1 loads р50 copies/mL, р10 copies/mL, and р3 copies/mL, a median decrease in HIV-1 load of 5.4 log copies/mL, and an HIV-1 load of 0.7 log copies/mL. Even during a conservative intentionto-treat analysis (with missing data counted as "failure"), 64% of the patients had an HIV-1 load р50 copies/mL at week 48-a result comparable to that found during chronic infection [25] .
Baseline parameters were helpful in forecasting virological outcome. Cell-associated HIV-1 RNA and DNA levels are indirect markers of treatment efficacy [7, 18] . Previous studies, including a study by Garrigue et al. [26] , have revealed a median HIV-1 mRNA level of 1.7 log copies/million PBMCs and detectable mRNA levels after 12 months of ART in some aviremic patients with PHI who received ART and in all patients with chronic infection who received ART [7, 20, [27] [28] [29] . We extend these results by revealing that plasma replication was dramatically decreased overall, because 33% of the patients had viral loads р3 copies/mL, and that the overall cell-associated RNA level decreased from 2.6 log copies/million PBMCs to 0.8 log copies/million PBMCs.
When looking at cell-associated DNA level, which reflects Figure 3 . Percentage of patients with plasma HIV-1 RNA loads (VL) р50 copies/mL, р10 copies/mL, and р3 copies/mL. The solid line represents data according to an intention-to-treat analysis, with missing data counting as "failure." The dotted line represents a "receiving antiretroviral therapy (ART)" analysis. The numbers of patients in the "receiving ART" analysis were 146, 133, 126, 120, 113, 104, 111 , and 100 at weeks 0, 4, 8, 12, 20, 28, 36, and 48, respectively. the reservoir size, we found a median decrease of the cellassociated DNA level of 1.1 log copies/million PBMCs and a cell-associated DNA level of 1.6 log copies/million PBMCs at the end of year 1. Previous studies of PHI have described a decrease of the cell-associated DNA level of ∼1.0 log after 18 months of ART, compared with the one-half log decrease and absence of undetectable levels during chronic infection [7, 20, 26, 27, [30] [31] [32] . Garrigue et al. [26] reported that, after 1 year of ART, cell-associated DNA levels were 2.0 log copies/million PBMCs, with 1 of 22 patients having a cell-associated DNA level !10 copies/million PBMCs; these findings contrast our figure of 6 patients (9.5%) with cell-associated DNA levels р3 copies/million PBMCs. Five of these 6 patients had a viral load !10 copies/mL at the time of proviral measurement. These patients did not differ in terms of baseline CD4 cell count and HIV-1 load from those who had detectable cell-associated DNA levels. Our results suggest that lower levels of cell-associated DNA are achievable with ART initiation during PHI than with ART initiation during chronic infection [7, 31, 32] . Our data also illustrate the changes in immune activation. Normalization of the CD8 + /CD38 ++ T cell count occurred in 28 (27.7%) of 101 patients at week 48. These cell counts decreased initially in parallel with viral load and continued to decrease in patients achieving a viral load р50 copies/mLbut not in patients with a viral load у3 copies/mL-and could, therefore, represent a sensitive indicator of residual viral replication [33, 34] . Patients with an undetectable cell-associated RNA level at week 42 indeed had lower CD8 + /CD38 ++ T cell counts at weeks 36 and 48, compared with those who had a detectable cell-associated RNA level at week 42. The initial follow-up of 6 patients who had stopped treatment prematurely suggested that the CD8 + /CD38 ++ T cell count tended to increase with subsequent viral load rebound (data not shown).
Safety is an important factor to consider when initiating early treatment. Grade 3 or 4 clinical and laboratory severe adverse events occurred in a substantial proportion of patients but were generally reversible, as previously reported [22] . The incidence of hypersensitivity to abacavir (3%) was comparable to that in other studies. The rate of severe adverse events in our study compares with that in a previous study in which 17 of 39 patients with acute and chronic infection experienced 19 severe adverse events; significant depression accounted for 2 severe adverse events [22] . In a French cohort study of PHI, 124 patients (51%) described having experienced at least 1 adverse event, and 19% of these events were reported as mood disorder [35] . The 14 psychiatric severe adverse events in our study were not considered to be related to study medication. Strong past confounding factors were present in 11 of 13 patients, revealing the potential for serious psychiatric events during the immediate postseroconversion phase in patients with a previous psychiatric history.
In conclusion, we have described the first-year outcome of a large cohort of patients who initiated a protease inhibitorbased, 4-drug ART regimen during PHI. Our results are very encouraging for achieving a very low HIV-1 load, considering the virological parameters in patients receiving ART, undetectable cell-associated RNA and DNA levels in a substantial proportion of patients and predictive value of proviral DNA, and CD8 + /CD38 ++ T cell count. This cohort data may serve as reference when using newer, simpler regimens with lower acute toxicity and activity during the preintegration stage. Future studies may also explore whether long-term treatment is associated with a continuous decrease of the viral reservoir and a potential absence of viral rebound after very prolonged ART.
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